These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
207 related articles for article (PubMed ID: 1965445)
21. [Value of tumor markers in monitoring of cytotoxic treatment of non-small cell lung cancer]. Załeska M Pneumonol Alergol Pol; 2003; 71(7-8):359-64. PubMed ID: 15052970 [No Abstract] [Full Text] [Related]
22. [Diagnostic value of combined detection of TPS, NSE and CEA in lung cancer]. Zheng H; He BF; Luo RC Di Yi Jun Yi Da Xue Xue Bao; 2003 Feb; 23(2):165-6. PubMed ID: 12581971 [TBL] [Abstract][Full Text] [Related]
23. Values and limits of combined use of 4 tumor markers (CEA, TPA, NSE and SCC) in un-treated patients with lung cancer. Cuomo A; Capra R; Greco S; Cacciani GC; Greco F; Franchini D; Bonelli P; Gavaruzzi G; Ugolotti G Acta Biomed Ateneo Parmense; 1993; 64(5-6):171-84. PubMed ID: 7992555 [No Abstract] [Full Text] [Related]
24. The diagnostic and prognostic value of ProGRP in lung cancer. Nisman B; Biran H; Ramu N; Heching N; Barak V; Peretz T Anticancer Res; 2009 Nov; 29(11):4827-32. PubMed ID: 20032442 [TBL] [Abstract][Full Text] [Related]
25. Pro-gastrin-releasing peptide (ProGRP), neuron specific enolase (NSE), carcinoembryonic antigen (CEA) and cytokeratin 19-fragments (CYFRA 21-1) in patients with lung cancer in comparison to other lung diseases. Schneider J; Philipp M; Velcovsky HG; Morr H; Katz N Anticancer Res; 2003; 23(2A):885-93. PubMed ID: 12820318 [TBL] [Abstract][Full Text] [Related]
26. Prognostic markers for stage I non-small cell lung cancer. Mizuguchi S; Nishiyama N Lung Cancer; 2008 Feb; 59(2):274-5. PubMed ID: 18055061 [No Abstract] [Full Text] [Related]
27. Serum biomarkers facilitate the recognition of early- stage cancer and may guide the selection of surgical candidates: a study of carcinoembryonic antigen and tissue polypeptide antigen in patients with operable non-small cell lung cancer. Buccheri G; Ferrigno D J Thorac Cardiovasc Surg; 2001 Nov; 122(5):891-9. PubMed ID: 11689793 [TBL] [Abstract][Full Text] [Related]
28. [Value of combined detection of tumor markers for the prediction of small cell and non-small cell lung cancer]. Wu Y; Wu Y; Wang L; Qu L Wei Sheng Yan Jiu; 2000 Jul; 29(4):213-5. PubMed ID: 12520921 [TBL] [Abstract][Full Text] [Related]
29. [Usefulness of monitoring levels of carcinoembryonic antigen, neuron-specific enolase and ferritin in serum of patients with small cell lung cancer for evaluating treatment outcome]. Szturmowicz M; Rogińska E; Roszkowski K; Kwiek S; Filipecki S; Rowińska-Zakrzewska E Pneumonol Alergol Pol; 1993; 61(9-10):489-95. PubMed ID: 8111325 [TBL] [Abstract][Full Text] [Related]
30. Fuzzy logic-based tumor marker profiles including a new marker tumor M2-PK improved sensitivity to the detection of progression in lung cancer patients. Schneider J; Peltri G; Bitterlich N; Neu K; Velcovsky HG; Morr H; Katz N; Eigenbrodt E Anticancer Res; 2003; 23(2A):899-906. PubMed ID: 12820320 [TBL] [Abstract][Full Text] [Related]
31. [The diagnostic values of CA242 combining other tumor markers for lung cancer]. Zhang S; Ma Y; Yang X Zhonghua Jie He He Hu Xi Za Zhi; 1999 May; 22(5):271-3. PubMed ID: 11775851 [TBL] [Abstract][Full Text] [Related]
32. [Tumor markers in lung cancer]. Niho S; Shinkai T Gan To Kagaku Ryoho; 2001 Dec; 28(13):2089-93. PubMed ID: 11791391 [TBL] [Abstract][Full Text] [Related]
33. Usefulness of a multiple biomarker assay in bronchoalveolar lavage (BAL) and serum for the diagnosis of small cell lung cancer. Nikliński J; Chyczewska E; Furman M; Kowal E; Laudanski J; Chyczewski L Neoplasma; 1993; 40(5):305-8. PubMed ID: 8272160 [TBL] [Abstract][Full Text] [Related]
34. The prognostic value of both neuron-specific enolase (NSE) and Cyfra21-1 in small cell lung cancer. Ando S; Suzuki M; Yamamoto N; Iida T; Kimura H Anticancer Res; 2004; 24(3b):1941-6. PubMed ID: 15274381 [TBL] [Abstract][Full Text] [Related]
35. [Dimorphous cancer of the lung]. Briusov PG; Leonova VV Vopr Onkol; 1997; 43(2):205-7. PubMed ID: 9214124 [TBL] [Abstract][Full Text] [Related]
36. [Relation between the level of TPS, NSE, CEA and beta2-mG in the serum and the biological behavior of small cell lung cancer]. Chen MS; Xu Y; Ma J; Wu CG; Hao XK; Lu BB; Liu T Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2007 Aug; 23(8):751-3. PubMed ID: 17618570 [TBL] [Abstract][Full Text] [Related]
37. Clinical evaluation of five tumor marker assay in patients with lung cancer. Mizushima Y; Tsuji H; Izumi S; Hirata H; Kin Y; Kawasaki A; Matsui S; Yano S Anticancer Res; 1991; 11(1):91-5. PubMed ID: 2018388 [TBL] [Abstract][Full Text] [Related]
38. Monitoring of therapy in inoperable lung cancer patients by measurement of CYFRA 21-1, TPA- TP CEA, and NSE. Ebert W; Hoppe M; Muley T; Drings P Anticancer Res; 1997; 17(4B):2875-8. PubMed ID: 9329552 [TBL] [Abstract][Full Text] [Related]
39. Utility of the serum tumor markers: CYFRA 21.1, carcinoembryonic antigen (CEA), and squamous cell carcinoma antigen (SCC) in squamous cell lung cancer. Tas F; Aydiner A; Topuz E; Yasasever V; Karadeniz A; Saip P J Exp Clin Cancer Res; 2000 Dec; 19(4):477-81. PubMed ID: 11277326 [TBL] [Abstract][Full Text] [Related]
40. Carcinoembryonic antigen, neuron-specific enolase and creatine kinase-BB as tumor markers for carcinoma of the lung. Nikliński J; Furman M; Palynyczko Z; Laudański J; Bułatowicz J Neoplasma; 1991; 38(6):645-51. PubMed ID: 1766488 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]